RHYTHM PHARMACEUTICALS INC

Insider buying spikes at Rhythm Pharmaceuticals, boosting confidence in its metabolic disorder pipeline and recent share rally.

Rhythm Pharmaceuticals’ insider trades show strategic buying and profitable selling, revealing executive confidence in its obesity and diabetes pipeline.

Insider buying shows confidence in Rhythm Pharmaceuticals amid market swings – see why the Mathers trust’s free‑cost purchase could signal future upside.

Rhythm Pharmaceuticals insider buying: EVP Mazabraud Yann’s 35,000 stock‑options signal leadership confidence, potential upside if FDA approval and global expansion succeed.

Mathers’ latest insider purchase of Rhythm Pharmaceuticals shows confidence in setmelanotide’s future, hinting at a long‑term upside amid FDA buzz.

Insider buy‑back at Rhythm Pharmaceuticals signals confidence in its setmelanotide obesity pipeline, hinting at upside as FDA filings loom.

Rhythm Pharmaceuticals CFO buys 6,099 shares, signaling confidence in its obesity/rare‑disease pipeline and a potential rebound ahead of Phase‑3 data.

Insider CFO Smith Hunter sells 4,000 Rhythm shares at $99.42, showing a steady liquidity plan and neutral market impact for investors.

Insider buying spree at Rhythm Pharmaceuticals shows execs betting on upcoming obesity‑drug milestones, offering upside potential despite current losses.

Insider CFO sells 4,631 Rhythm shares—plan‑based move amid 52‑week highs, negative earnings, and uncertain pipeline milestones.